Effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms.
Infection of medical implanted material is associated with considerable morbidity and costs. In the following work, we investigated the effects of vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on biofilms formed by Staphylococcus epidermidis isolates causative for implant infection and catheter-associated bacteremia. Biofilms were studied using the static microtiter plate model and incubated with the antibiotics increasing the concentration from 1x to 128 x the minimal inhibitory concentration (MIC) of the respective isolate tested. To quantify the reduction of the biomass, the optical density ratio (ODr) of stained biofilms and the number of growing bacteria were determined. Incubation of the staphylococcal biofilms with the antibiotics decreased the biofilm ODr (at baseline = 1) for ceftriaxone (0.83 +/- 0.48) but minimally only for fosfomycin (0.96 +/- 0.64), daptomycin (1.05 +/- 0.59), tigecycline (1.18 +/- 0.66), and vancomycin (0.98 +/- 0.44) at exceedingly high concentrations of 128 x MIC. The significant reduction of the bacterial growth was not achieved for all antibiotics, not even at the highest concentrations tested. Using higher doses of the antibiotics may be of some value in the treatment of biofilm-associated infections, although effects are seen only at clinically unachievable doses. However, to eradicate the staphylococcal biofilm, additional measures like debridement and/or removal of the implant are needed.
Hajdu
Stefan
S
Department of Trauma Surgery, Medical University of Vienna, Vienna, Austria.
Lassnigg
Andrea
A
Graninger
Wolfgang
W
Hirschl
Alexander M
AM
Presterl
Elisabeth
E
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects*; D002443:Ceftriaxone / Q000494:pharmacology; D017576:Daptomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005578:Fosfomycin / Q000494:pharmacology; D006801:Humans; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D012867:Skin / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000502:physiology*; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005578:Fosfomycin; D014640:Vancomycin; D000078304:Tigecycline; D002443:Ceftriaxone; D008911:Minocycline; D017576:Daptomycin